CERN has announced that they are to release a cut-down version of their popular Hadron Collider for use in the home.
The Large Hadron Collider was built over twenty years ago, is housed in a 27-kilometre tunnel on the Switzerland – France border, and is used to smash particles together to see what happens.
The facility has proven tremendously successful, having smashed over thirty particles together since it was built.
A critical security flaw in the Bricks theme for WordPress is being actively exploited by threat actors to run arbitrary PHP code on susceptible installations.
The flaw, tracked as CVE-2024–25600 (CVSS score: 9.8), enables unauthenticated attackers to achieve remote code execution. It impacts all versions of the Bricks up to and including 1.9.6.
It has been addressed by the theme developers in version 1.9.6.1 released on February 13, 2024, merely days after WordPress security provider Snicco reported the flaw on February 10.
The Anatsa banking trojan has been targeting users in Europe by infecting Android devices through malware droppers hosted on Google Play.
Over the past four months, security researchers noticed five campaigns tailored to deliver the malware to users in the UK, Germany, Spain, Slovakia, Slovenia, and the Czech Republic.
Researchers at fraud detection company ThreatFabric noticed an increase of Anatsa activity since November, with at least 150,000 infections.
The Cactus ransomware gang claims they stole 1.5TB of data from Schneider Electric after breaching the company’s network last month.
25MB of allegedly stolen were also leaked on the operation’s dark web leak site today as proof of the threat actor’s claims, together with snapshots showing several American citizens’ passports and non-disclosure agreement document scans.
As BleepingComputer first reported, the ransomware group gained access to the energy management and automation giant’s Sustainability Business division on January 17th.
MIT researcher Richard Binzel has studied near-Earth asteroids for more than five decades and believes they could one day act as “space filling stations.”
Ever wonder what it’s like to live on Mars? Now, you could try out life on the Red Planet – in a simulation run by NASA. The space agency is looking for participants to live on a fake Mars for a full year to help them prepare for human exploration of the planet.
This is the second of three missions, which will have four volunteers living in a 1,700-square-foot Mars simulation, NASA has announced. The missions, called CHAPEA, for Crew Health and Performance Exploration Analog, take place in a 3D-printed Mars habitat at NASA’s Johnson Space Center in Houston, Texas.
The simulation, called the Mars Dune Alpha, simulates a future Mars habitat with separate areas for living and working. It includes four living quarters for each volunteer, a workspace, a medical station, lounge areas and a galley and food growing stations.
NEJM Journal Watch Oncology and Hematology Associate Editor David Ilson was on hand at the 2024 ASCO Gastrointestinal Cancers Symposium and highlights the latest research in colorectal, neuroendocrine, and esophagogastric cancers.
Important new studies with the potential to impact clinical practice were presented at the 2024 ASCO Gastrointestinal Cancers Symposium held January 18 to 20 in San Francisco. NEJM Journal Watch Oncology and Hematology Associate Editor David H. Ilson, MD, PhD, was on hand and reports on some of them.
COLORECTAL CANCER
Researchers presented results from CheckMate 8HW, an industry-sponsored, international, open-label, phase 3 trial evaluating first-line treatments in patients with microsatellite instability (MSI)-high/DNA mismatch repair protein-deficient metastatic colorectal cancer. Patients were randomized to investigator’s choice of chemotherapy (mFOLFOX6 or FOLFIRI, with or without bevacizumab or cetuximab), single-agent nivolumab (240 mg every 4 weeks followed by 480 mg monthly), or nivolumab combined with ipilimumab (1 mg/kg for 4 doses). An interim analysis was presented for the 303 patients treated with chemotherapy or ipilimumab/nivolumab.
Lung cancer is the deadliest of cancers. Screening could save thousands of lives, so why is it not the norm?
Lung cancer kills more people than any other form of tumour.
About nine out of ten people die within five years of being diagnosed with the disease. If the cancer is caught very early most patients could be cured. But doctors struggle to diagnose early because there are no symptoms until the cancer is in its late stages and has spread to other organs.
Some experts think that doctors should screen people at high risk to find lung cancer before symptoms appear. The national lung-screening trial in America subjected 53,000 current and former heavy smokers to either X-ray or computed-tomography scans every year for three years. Its results, reported in 2011 found that screening with CT scans did save lives.
New research from the University of Sussex holds promise for extending life expectancy and enhancing treatment options for a common and aggressive brain cancer affecting thousands in the UK annually and hundreds of thousands globally.
Published in the Journal of Advanced Science, the study revealed that the protein PANK4, previously overlooked, can hinder cancer cells’ response to chemotherapy in glioblastoma, an aggressive form of brain cancer and if the protein is removed, cancer cells respond better to the main chemotherapy drug used globally for the treatment of glioblastoma.
Glioblastoma stands as one of the most aggressive types of brain cancer, with approximately 3,200 adults diagnosed annually in the UK and around 250,000 to 300,000 cases globally. Despite treatment with surgery, radiation, and the chemotherapy drug temozolomide, which initially yields positive responses, patients typically face a bleak prognosis, with a survival rate of just one to 18 months post-diagnosis due to the rapid development of resistance in cancer cells.
Memorial Sloan Kettering Cancer Center made waves earlier this year when it announced the completion of a clinical trial that saw colorectal cancer in 18 patients disappear.
The patients received a drug that helped their immune system target and attack cancer cells, driving their cancer into remission and rendering it undetectable within six months.
Now, Lehigh Valley Health Network has joined a select group of networks and hospitals participating in the expanded clinical trial of the drug.
